Vemurafenib was identified as a selective inhibitor of BRAFV600E more than a decade ago, and has been proven to work effectively in BRAF mutated melanoma, although resistance to Vemurafenib develops rapidly [9,10,11]. Here, BRAF is linked to melanoma.